Cancer Patents (Class 436/813)
-
Patent number: 4861710Abstract: The invention provides a recombinant cDNA clone encoding cell surface receptor for laminin, as well as a probe and methods of using that probe to diagnose the aggressiveness of a carcinoma or the effectiveness of an agent for treating cancer cells.Type: GrantFiled: September 26, 1986Date of Patent: August 29, 1989Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Mark E. Sobel, Lance A. Liotta, Ulla M. Wewer, Michael C. Jaye, William N. Drohan
-
Patent number: 4857452Abstract: Colorectal, breast or ovarian cancer can be detected by means of a blood, plasma, serum, urine or feces assay for elevated levels of 47D10 antigen using a monoclonal antibody to the antigen.Type: GrantFiled: December 4, 1986Date of Patent: August 15, 1989Assignee: E. I. Du Pont de Nemours and CompanyInventor: May-Kin Ho
-
Patent number: 4857457Abstract: The disaccharide .beta.-D-Gal (1->>3)-D-GalNAc, which specifically binds with peanut agglutinin (PNA) or oxidized by galactose oxidase, has been discovered in the colorectal mucus of patients with cancer or precancer. Because of the presence of .beta.-D-Gal-(1>>3)-D-GalNAc also on neuraminidase treated erythrocytes of the ABO type, their competitive binding with PNA has been exploited to develop a hemagglutination inhibition assay. Additional methods of simple detection of this disaccharide include a latex agglutination test, enzyme-avidin-biotinylated PNA, and a galactose oxidase strip test. This rapid, simple and inexpensive assay is designed to test the presence of .beta.-D-Gal-(1>>3)-D-GalNAc in large intestine mucus obtained by routine digital-rectal examination and has the potential for screening populations for large intestinal carcinomas.Type: GrantFiled: July 24, 1986Date of Patent: August 15, 1989Inventors: Abulkalam M. Shamsuddin, Alaaeldeen M. Elsayed, Glenn A. Jockle
-
Patent number: 4857466Abstract: Gene probes containing genetic sequences that code for proteins which are phenotypically characteristic of certain leukemias, such as chronic myelogenous leukemia, can be prepared from RNA of a person having that disease. The gene probes can be used in diagnostic hybridization tests with RNA of a patient to be diagnosed.Type: GrantFiled: September 4, 1987Date of Patent: August 15, 1989Assignee: The Board of Regents of the University of Texas SystemInventors: Grady F. Saunders, Wendy M. Mars
-
Patent number: 4855241Abstract: An in vitro diagnostic method for determining the presence of nerve growth factor receptor bearing tumors is disclosed which comprises determining the presence of an elevated level of a truncated nerve growth factor receptor in a sample of a body fluid from a patient afflicted with such tumor.Type: GrantFiled: May 26, 1988Date of Patent: August 8, 1989Assignee: Washington UniversityInventor: Eugene M. Johnson, Jr.
-
Patent number: 4853325Abstract: The saliva test for feline leukemia virus (FeLV) employs a probe having an immunochemically sensitive member for collecting saliva from the oral cavity of a cat and employs ELISA reagents for the incubation of the probe and the development of color reactions to indicate the presence or absence of FeLV within the saliva sample collected onto the probe.Type: GrantFiled: March 26, 1986Date of Patent: August 1, 1989Assignee: Synbiotics CorporationInventors: Morton A. Vodian, Eric S. Bean, Eric D. LeMoine
-
Patent number: 4851356Abstract: An immunoassay for detecting and measuring hCG in a sample includes an antibody directed to the carboxy terminal portion of the .beta. subunit of hCG and a monoclonal antibody directed to a determinant on hCG at a locus sufficiently remote from the carboxy terminal portion of the .beta. subunit of hCG that both antibodies can simultaneously bind to hCG, wherein at least one of the antibodies is delectable when both are bound to hCG.In a presently preferred embodiment, an immunoassay for hCG or hCB.beta. in urine includes a purified, labeled or detectable serum-derived antibody directed to the carboxy-terminal portion of the .beta. subunit of hCG and a matrix-bound monoclonal antibody directed to a locus on the .beta. subunit sufficiently remote from the carboxy-terminal portion that both antibodies can simultaneously bind to hCG or hCG.beta..Type: GrantFiled: July 14, 1987Date of Patent: July 25, 1989Assignee: The Trustees of Columbia University in the City of New YorkInventors: Robert E. Canfield, Elmo G. Armstrong, Paul H. Ehrlich, Steven Birken
-
Patent number: 4845026Abstract: Methods are provided for detecting and determining the amount in a sample of an antigenic determinant from an antigen receptor derived and released from a T cell or NK cell. Methods are also provided for detecting and determining the amount in a sample of an antigenic determinant from a complex of at least a portion of an antigen receptor derived from and released from a T cell or NK cell and a protein complex. These methods form the bases for methods of diagnosing and monitoring in a subject a disease characterized by the presence or an amount different from a normal subject of one of these antigenic determinants in a body fluid. A soluble antigen receptor or complex thereof derived from a T cell or a NK cell but free of such T cell or NK cell is also provided.Type: GrantFiled: December 3, 1985Date of Patent: July 4, 1989Assignee: T Cell Sciences, Inc.Inventors: Patrick C. Kung, Michael C. Brown, Stephen H. Ip
-
Patent number: 4843019Abstract: The invention relates to acino-fetal differentiation proteins associated with cancer of the pancreas, these proteins being mannoside-containing glycoproteins of average apparent molecular mass chosen from: 120 KD, 94 KD and 58 KD.The invention also relates to a method for preparing these proteins, an antiserum against these proteins and the method for preparation thereof, monoclonal antibodies against these proteins and the method for preparation thereof, and compositions for diagnostic or therapeutic use containing these proteins or antibodies.Type: GrantFiled: May 29, 1986Date of Patent: June 27, 1989Assignee: Centre National de la Recherche ScientifiqueInventors: Maria J. Escribano-Crespo, Pierre Burtin
-
Patent number: 4840915Abstract: This invention is directed to a novel group of compounds, herein termed Recognins. Recognins are made by treating malignant tumor cells or artificial cancer cells and separating the desired products. The Recognins may be used to prepare their Chemoreciprocals, i.e., by contacting the Recognins or the Recognins on a support with body fluids. These Chemoreciprocals are useful for diagnostic and therapeutic purposes, i.e., for diagnosing and treating cancers. The Chemoreciprocals are substances which react with immunochemical-like specificity with a Recognin in vivo or in vitro, e.g., in a quantitative precipitin test, in Ouchterlony double diffusion or in immunofluorescence.Type: GrantFiled: October 3, 1983Date of Patent: June 20, 1989Assignee: Brain Research, Inc.Inventor: Samuel Bogoch
-
Patent number: 4837003Abstract: Methods and reagents for attaching radionuclide metal ions to antibody fragments are disclosed. A coupling agent is employed which contains a maleimidyl group linked, through a divalent organic moiety, to a group capable of forming a chelate complex with the radionuclide metal ion. Antibody fragments labeled with radionuclide metal ions by the disclosed procedure are useful for in vivo diagnostic or therapeutic applications.Type: GrantFiled: September 13, 1984Date of Patent: June 6, 1989Assignee: Mallinckrodt, Inc.Inventor: Robert A. Nicolotti
-
Patent number: 4837306Abstract: The invention provides a method for selecting hybridomas which produce antibodies specific to domains of a cell surface antigen which is usually not accessible at the surface of intact cells. The method employs the screening of the hybridoma clones obtained for the production of antibodies specific against the cell surface antigen by use of immunoblotting analysis, namely by screening the clones against antigen immobilized on a solid substrate such as nitrocellulose. The invention also includes those hybridomas and monoclonal antibodies when produced according to the method. The method provides monoclonal antibodies to P-glycoprotein surface antigen correlated with multidrug resistance. The antibodies are used to obtain a cDNA probe which in turn was used to select a cDNA clone encoding for a portion of the P-glycoprotein including the C-terminal end.Type: GrantFiled: November 10, 1986Date of Patent: June 6, 1989Assignee: The Ontario Cancer InstituteInventors: Victor Ling, Norbert Kartner
-
Patent number: 4828991Abstract: Monoclonal antibodies produced by hybridoma or transformed B-cell lines deriveed from B-cells of cancer patients actively immunized with autologous tumor antigen. These monoclonal antibodies can be used in both diagnostic procedures and therapy for human cancers.Type: GrantFiled: January 31, 1985Date of Patent: May 9, 1989Assignee: Akzo N.V.Inventors: Michael Hanna, Jr., Martin V. Haspel, Herbert C. Hoover, Jr.
-
Patent number: 4820631Abstract: Specific deletion mutants of ras p21 gene and specific monoclonal antibodies which recognize specific regions of the ras p21 protein have been prepared. A kit for detecting the presence of specific ras p21 proteins and their levels in a body sample has been described.Type: GrantFiled: July 30, 1986Date of Patent: April 11, 1989Assignee: The United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Juan C. Lacal, Stuart A . Aaronson
-
Patent number: 4818682Abstract: An in vitro diagnostic method for detecting the presence in a patient of cancer cells or other cells producing mucin antigens comprises the step of testing a sample of a physiological fluid, particularly a sample of blood, blood serum or blood plasma, taken from the patient to detect the presence of small intestine mucin antigen (SIMA) and/or large intestine mucin antigen (LIMA) in the sample. An in vitro diagnostic kit is also disclosed.Type: GrantFiled: April 24, 1986Date of Patent: April 4, 1989Assignee: Mucan Diagnostics Pty., Ltd.Inventor: Anthony W. Linnane
-
Patent number: 4818677Abstract: Methods and kits are described for performing immunoassays. The kit includes a reaction cell having a microporous membrane and an absorbent capable of drawing liquid sample through the membrane. An applicator is provided for applying a small volume of the liquid sample to the membrane by contacting a port of the applicator to the membrane and allowing the sample to flow therethrough by capillary action. Analyte in the sample is immobilized, typically by immunoadsorption, and the immobilized analyte may then be visualized using conventional signal producing systems, such as color, fluorescence, and luminescent systems.Type: GrantFiled: December 3, 1987Date of Patent: April 4, 1989Assignee: Monoclonal Antibodies, Inc.Inventors: Martha L. Hay-Kaufman, Rosette Becker, Robert Danisch
-
Patent number: 4816402Abstract: Hybridoma HB 8986 produces a murine monoclonal antibody which recognizes a new determinant expressed in bronchopulmonary carcinomas and A549 cell line derived tumors. Immunoperoxidase staining with the hybridoma on formalin fixed, paraffin embedded tissues shows that it specifically stains both the cytoplasmic and cell surface. The monoclonal antibody has the ability to distinguish preferably bronchopulmonary carcinomas with glandular differentiation from other bronchopulmonary carcinomas. Additionally, the monoclonal antibody may identify adenocarcinomas through the body.Type: GrantFiled: January 7, 1986Date of Patent: March 28, 1989Assignee: Northwestern UniversityInventors: Steven T. Rosen, James A. Radosevich, Yixing Ma
-
Patent number: 4816390Abstract: An immunochemical assay of human carcinoembryonic antigen (CEA), comprising the use of an antibody supported on a carrier and an antibody labelled with peroxidase by coupling by means of a compound of the formula: ##STR1## wherein n is an integer of 0 to 5 and R is a chemical bond or a divalent 6-membered cyclic hydrocarbon residue, in which at least one of said antibodies is a monoclonal antibody. The assay can be conducted with high sensitivity by simple and easy operation in clinical laboratories.Type: GrantFiled: April 10, 1985Date of Patent: March 28, 1989Assignee: Takeda Chemical Industries, Ltd.Inventors: Koichi Kondo, Nobuhiro Suzuki
-
Patent number: 4816395Abstract: As assay for determining the sensitivity of an individual patient tumor to particular chemotherapeutic drugs relies on growth of the neoplastic tumor cells in a mass culture. The mass culture medium provides metabolites essential for the growth of the cells, even in the presence of the particular drug being tested, which is usually an anti-metabolic drug. The mass culture of cells is exposed to a labelled analog of the drug, and the uptake of the labelled drug analog determined. By comparing the amount of the drug uptake by the neoplastic cells with that of the corresponding normal cells, drug sensitivity may be assessed. The method is particularly useful with fluorescently-labelled drugs where the uptake may be assessed by use of a fluorescence activated cell sorter.Type: GrantFiled: December 19, 1985Date of Patent: March 28, 1989Assignee: Peralta Cancer Research InstituteInventors: Miriam E. C. Hancock, Helene S. Smith, Adeline J. Hackett
-
Patent number: 4814269Abstract: A method of testing a fluid sample for the presence of antibodies against a micro-organism, which comprises contacting the sample with fixed cells or fragments of cells infected with the micro-organism, and determining the presence of antibody bound to the cell-associated antigens, in which the determination is by virtue of a color change visible to the naked-eye at the site of the antibodies. For use in a testing method of this type, a test component comprises upper and lower layers, in which the upper layer has an array of apertures through which discrete areas on the lower layer are exposed, and in which the lower layer carries, in some at least of the discrete areas, fixed cells or cell fragments infected by a micro-organism.Type: GrantFiled: March 21, 1986Date of Patent: March 21, 1989Assignee: Cenfold Holdings S.A.Inventor: Abraham Karpas
-
Patent number: 4808528Abstract: Basement membrane collagen degrading enzymes are provided which are useful for the detection of malignant cells with metastatic activity. Means for detecting such cells are also provided.Type: GrantFiled: June 26, 1987Date of Patent: February 28, 1989Inventors: Karl Tryggvason, Lance A. Liotta
-
Patent number: 4806464Abstract: A method for rapidly determining the presence of functional cellular steroid receptors by assaying a tissue sample for nuclear steroid or antisteroid binding is disclosed which comprises treating the tissue with collagenase, incubating the isolated cells with a labelled steroid or a labelled antisteroid capable of complexing said receptors and measuring the bound nuclear radioactivity and the DNA of the isolated cellular nuclei.Type: GrantFiled: February 11, 1987Date of Patent: February 21, 1989Assignee: Mayo Foundation for Medical Education and ResearchInventor: Thomas C. Spelsberg
-
Patent number: 4806492Abstract: Novel polypeptides, polynucleotide sequences, DNA constructs and compositions are provided for the preparation and use of polypeptides associated with naturally occurring polypeptides found in brains. The small molecular weight polypeptides are growth inhibitors for neoplastic cells without inhibiting normal cells. The polypeptides comprise specific regions which are highly conserved, separated by less conserved regions. The polypeptides find use in inhibiting neoplastic growth and detecting receptors for the polypeptides. Antibodies are provided in conjunction with the polypeptides, which may be used together or separately for detecting the presence of the neoplastic cell retarding polypeptides.Type: GrantFiled: August 15, 1985Date of Patent: February 21, 1989Assignee: Oncogen, Inc.Inventors: Mohammed Shoyab, Hans Marquardt, George J. Todaro
-
Patent number: 4804626Abstract: A highly sensitive and specific monoclonal-immuno-radiometric assay (M-IRMA) for hCG, using monoclonal antibodies (Mabs) directed against a 37-amino acid synthetic polypeptide analogous to the carboxyl terminus (CTP) of beta-hCG. Accordingly, in one embodiment, a method is described for the determination of human chorionic gonadotrThe present invention was made utilizing funds of the United States Government. The U.S. government is therefore granted a royalty-free, non-exclusive, world wide, paid-up license in this invention.Type: GrantFiled: October 22, 1986Date of Patent: February 14, 1989Assignee: The General Hospital CorporationInventors: Dominique Bellet, Jack R. Wands, Mehmet Ozturk
-
Patent number: 4803169Abstract: Methods are disclosed for detecting, staging and monitoring breast cancer. The methods involve determining the amount of certain antigens, designated W1 and W9, in serum via quantitative immunoassays using anti-W1 or anti-W9 monoclonal antibodies. The amount detected is compared with amounts of the antigen found in normal sera, sera from breast cancer patients of predetermined stage, or other samples of the patient's own serum, depending upon the purpose of the assay.Type: GrantFiled: February 5, 1986Date of Patent: February 7, 1989Assignee: Cetus CorporationInventors: Peter S. Linsley, Vincent W. Ochs, Diane Horn, Joseph P. Brown, David B. Ring, Arthur E. Frankel
-
Patent number: 4800155Abstract: A human-mouse hybridoma producing a human monoclonal antibody specific for human lung squamous and adenocarcinomas. The human monoclonal antibody can be utilized as a diagnostic agent in serological diagnosis, in the radioimmaging of lung tumors or as a therapeutic agent.Type: GrantFiled: February 9, 1987Date of Patent: January 24, 1989Assignees: Yoshitomi Pharmaceutical Industries, Ltd., Masaru TaniguchiInventors: Masaru Taniguchi, Hiroaki Saito, Yutaka Yamaguchi, Fumio Hiraoka, Ikuro Nakamura
-
Patent number: 4798790Abstract: Monoclonal antibody TA99, which specifically binds to a pigmentation associated antigen present on melanoma cells is described. Additionally, the hybridoma cell line deposited with the ATCC under Accession Number HB 8704 from which the antibody is derived, as well as methods for using the antibody are described.Type: GrantFiled: July 18, 1985Date of Patent: January 17, 1989Assignee: Sloan-Kettering InstituteInventors: Timothy M. Thomson, M. Jules Mattes, Lloyd J. Old, Kenneth O. Lloyd, Linda Roux
-
Patent number: 4798787Abstract: Antibodies exhibit specificity toward single amino acid differences between proteins. These antibodies may be produced by synthesizing a peptide of the appropriate amino acid sequence contained in the protein, immunizing a host with the peptide, and extracting sera from the host to obtain the antibodies. The antibodies and the desired protein are then immunoprecipitated under conditions of partial denaturation to expose the epitope of the protein. The antibodies may be used for diagnostic or therapeutic purposes.Type: GrantFiled: October 17, 1984Date of Patent: January 17, 1989Assignee: Cetus CorporationInventors: Francis P. McCormick, Gail L. Wong, Robin Clark, Norman Arnheim, Danute E. Nitecki
-
Patent number: 4797356Abstract: Murine monoclonal antibodies specific to the tumor marker galactosyltransferase II (GT-II) which have no measurable cross-reactivity with galactosyltransferase I (GT-I) are described. These antibodies are used in assays to determine levels of GT-II in serum or other body fluid samples, which levels, depending on their magnitude, are indicators of cancer.Type: GrantFiled: December 2, 1985Date of Patent: January 10, 1989Assignee: Konishiroku Photo Industries, Co., LtdInventors: Alan E. Brandt, Morito Uemura
-
Patent number: 4794077Abstract: Specific common nucleolar antigens are found in a broad range of human malignant tumor specimens and have been isolated, extracted and purifed. Monoclonal antibodies specific to one of these nucleolar antigens (p145) are harvested from mouse ascites or culture supernatant and used for detection of humanThe Government may have rights in this invention subject to funding grants provided by the Department of Health and Human Services No. 5 PO1-CA-10893-19.Type: GrantFiled: December 13, 1985Date of Patent: December 27, 1988Assignee: Biosciences Corporation of TexasInventors: Harris Busch, James W. Freeman, Rose K. Busch
-
Patent number: 4794074Abstract: The present invention discloses a method and a kit for monitoring human exposure to genotoxic agents. The method comprises an immunoassay for detecting in human serum specific antibodies against DNA adducted to an agent suspected of being genotoxic. A kit comprising various components for performing the assay is also disclosed.Type: GrantFiled: September 23, 1985Date of Patent: December 27, 1988Assignee: The United States of America as represented by the Department of Health and Human ServicesInventor: Curtis C. Harris
-
Patent number: 4791066Abstract: Disclosed is a method for diagnosing and differentiating cancer by qualitative and quantitative determination according to an immuno-serological assay of cancer-related antigens in a body fluid, particularly glycoprotein, glycolipid and glycoantigen produced by cancerization or dedifferentiation of normal cells.Type: GrantFiled: August 6, 1985Date of Patent: December 13, 1988Assignee: Kyowa Medex Co., Ltd.Inventor: Tatsuya Ishiguro
-
Patent number: 4786593Abstract: It has been determined that nerve growth factor binds to a cell surface protein of human neural crest origin having a molecular weight of about 75,000 daltons. New monoclonal antibodies specifically imunoprecipitate these receptor molecules, and also inhibit binding of the hormone to the receptor. These monoclonal antibodies show significantly higher reactivity with primary and metastatic melanoma cell lines than with melanocytes. The antibodies are used in a diagnostic method for histochemical detection of human neural crest disease.Type: GrantFiled: April 16, 1985Date of Patent: November 22, 1988Assignee: Wistar Institute of Anatomy and BiologyInventors: Alonzo Ross, Hilary Koprowski, Meenhard Herlyn
-
Patent number: 4786590Abstract: Specific binding members are provided for binding to lymphocytic cell surface receptors, which receptors are involved in the activation of a cell from the G.sub.0 state into the cell division cycle to proliferate. The cell surface receptors are further characterized by binding to envelope proteins of neoplasia-causing retroviruses, and/or to intact retroviral particles.Type: GrantFiled: January 15, 1985Date of Patent: November 22, 1988Assignees: California Institute of Technology, The Board of Trustees of the Leland Stanford, Jr. UniversityInventors: Michael S. McGrath, Irving L. Weissman
-
Patent number: 4784940Abstract: Methods and techniques are described for detecting the presence of cancer procoagulant activity in blood serum. The method provides a means of distinguishing persons or animals having cancer from those who do not have cancer. The method involves techniques for processing serum such that the activity of cancer procoagulant can be measured while the activity of other coagulation enzymes in the serum is minimized or eliminated. Then the serum can be analyzed for cancer procoagulant activity.Type: GrantFiled: June 26, 1987Date of Patent: November 15, 1988Assignee: Mesa Medical, Inc.Inventor: Stuart G. Gordon
-
Patent number: 4783420Abstract: An immunoassay for a carbohydrate antigenic determinant, such as CA 19-9, is disclosed in which the primary antigen-antibody reaction is carried out under acidic conditions.Type: GrantFiled: October 20, 1986Date of Patent: November 8, 1988Assignee: Centocor, Inc.Inventors: Bert C. DelVillano, Jr., Yu-Sheng V. Liu
-
Patent number: 4783419Abstract: Disclosed herein is a method for examining cells, comprising subjecting the cells to an antigen-antibody reaction treatment, then measuring a pattern of the electrophoretic mobility of the cells and comparing the electrophoretic property of the cells under examination with the electrophoretic property of standard cells.Type: GrantFiled: March 21, 1985Date of Patent: November 8, 1988Assignee: Kureha Kagaku Kogyo Kabushiki KaishaInventors: Haruhisa Hayashi, Yoshiharu Oguchi, Kenichi Matsunaga, Chikao Yoshikumi
-
Patent number: 4782015Abstract: The present invention is concerned with a method for determining the presence of a malignant condition at a locus of interest. An exfoliative cell specimen obtained from the locus is contacted with an antibody specific for an antigenic site that is usually only found in the specimen when a malignant condition is present. The contact is made under conditions for detectable binding of the antibody to such antigenic site. After contact, the presence of binding of the antibody to the antigenic site is observed. The binding of the antibody is related to the presence of a malignant condition at the locus. The invention finds utility, for example, in the detection of cervical carcinoma.Type: GrantFiled: March 30, 1984Date of Patent: November 1, 1988Assignee: Syntex (U.S.A.) Inc.Inventors: Anthony C. Allison, Vera Morhenn, Alain B. Schreiber
-
Patent number: 4777127Abstract: A human endogenous retrovirus-related Mv-75,000 protein, containing the decapeptide sequence Glutamic Acid-Asparagine-Proline-Serine-Glutamine-Phenylalanine-Tyrosine-Glutamic Acid-Arginine-Leucine, a synthetic undecapeptide Sp-23 based on the decapeptide, and specific polycolonal and monoclonal antibodies and specific nucleic acid probes are used as specific reagents for the detection and treatment of tumors such as renal cell adenocarcinoma and choriocarcinoma, among others, and placental disorders including blighted ova, hydatiform and destructive moles.Type: GrantFiled: September 30, 1985Date of Patent: October 11, 1988Assignee: Labsystems OyInventors: Jukka Suni, Antti Vaheri
-
Patent number: 4775620Abstract: Methods and compositions are provided for identifying patients suffering from neoplastic diseases such as breast cancer. It has been found that neoplastic epithelial cells, including neoplastic mammary epithelial cells, release a particular N-terminal blocked, soluble cytokeratin into circulation. The presence of this cytokeratin is diagnostic of neoplastic disease.Type: GrantFiled: January 30, 1985Date of Patent: October 4, 1988Assignee: The Regents of the University of CaliforniaInventors: Robert D. Cardiff, Paul V. Rossitto, Alan C. Brabon
-
Patent number: 4774176Abstract: A more convenient, more sensitive test for detection of certain malignancies in human and animal subjects is disclosed. Sera from test subjects is mixed with labeled DNA in the presence of an enzyme-conjugated matrix. Sera from normal and cancerous subjects react differently with the matrix, permitting a diagnosis of the subject.Type: GrantFiled: September 13, 1984Date of Patent: September 27, 1988Inventor: A. Arthur Gottlieb
-
Patent number: 4772559Abstract: A novel method of detecting and diagnosing lung cancers by monitoring and analyzing expired lung air for the presence of selected aromatic amines, particularly aniline and ortho-toluidine, is provided.Type: GrantFiled: March 31, 1987Date of Patent: September 20, 1988Assignees: Monell Chemical Senses Center, University of PennsylvaniaInventors: George Preti, John N. Labows, Ronald Daniele, James G. Kostelc
-
Patent number: 4757003Abstract: A process for the detection of cancer comprises an immunological assay of a glycolipid present in blood, thoracic cavity fluid, abdominal dropsy or urine wherein the glycolipid can be any one selected from the group consisting of:(1) asialo GM.sub.1 : galactosyl-N-acetylgalactosaminyl-galactosyl-glucosyl-ceramide;(2) asialo GM.sub.2 : N-acetylgalactosaminyl-galactosyl-glucosyl-ceramide;(3) fuco GA.sub.1 : fucosyl-galactosyl-N-acetylgalactosaminyl-galactosyl-glucosyl-ceramide; and(4) paragloboside: galactosyl-N-acetylglucosaminyl-galactosyl-glucosyl-ceramide.These glycolipids have been found to increase in body fluids with a proliferation of cancer cells.Type: GrantFiled: May 8, 1986Date of Patent: July 12, 1988Assignee: Dainabot Co., Ltd.Inventors: Makoto Matsumoto, Takao Taki, Kenji Arai, Hidemi Ishikawa, Kunio Kurata, Kiyoshi Sekiguchi, Akio Myoga, Kimimichi Obata
-
Patent number: 4757000Abstract: An improved assay for an ATL virus antibody in a specimen, in which an ATL virus antigen is added to the test specimen and used as a comparative specimen. This improved method selectively assays ATL virus antibodies, and, thus, is useful in preventing and treating adult T cell leukemia.Type: GrantFiled: May 22, 1985Date of Patent: July 12, 1988Assignee: Eisai Co., Ltd.Inventors: Junichi Tohmatsu, Takashi Sawada, Isao Miyoshi, Hirokuni Taguchi
-
Patent number: 4752569Abstract: Detection of sialylated Lewis.sup.x antigen in sera is employed as diagnostic of the presence of cancer. Conveniently, monoclonal antibodies are provided which are shown to be useful in the diagnosis of a neoplastic condition, with a wide variety of different tumors.The hybridoma CSLEX1 was deposited at the A.T.C.C. on June 20, 1984 and given Accession No. HB8580.Type: GrantFiled: June 21, 1984Date of Patent: June 21, 1988Assignee: The Regents of the University of CaliforniaInventors: Paul I. Terasaki, Masaki Hirota, Kiyoyasu Fukushima, Akemi Wakisaka, Takashi Iguro
-
Patent number: 4752565Abstract: Leu-3.sup.- cells surviving infection with the AIDS retrovirus can be induced with IUdR to express infectious virus. A cellular clone (8E5), isolated by limiting dilution of a mass culture of survivor cells, was found to contain a single, integrated, defective provirus that was consitutively expressed. Although IUdR treatment of 8E5 cells failed to induce infectious virus, cocultivation with Leu-3.sup.+ generated the characteristic syncytia associated with acute AIDS retrovirus infention. The single integrated copy of proviral DNA directs the synthesis of all major viral structural proteins except p64 and p34 as monitored by immunoblotting. Diagnostic reagents and kits in accordance with the present invention are also described.Type: GrantFiled: April 7, 1986Date of Patent: June 21, 1988Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Thomas M. Folks, Douglas M. Powell, Malcolm A. Martin
-
Patent number: 4748112Abstract: Regression associated antigens are identified in material from neoplastic cells by their immunological reactivity with regression associated antibodies from the serum of patients diagnosed as undergoing regression of a tumor. Regression associated antibodies are identified by their absence during progression of a neoplastic disease state and by their presence in a diagnosed state of regression. The antigens are purified, used to monitor the condition of cancer patients, and production of antibodies and treatments employing those antibodies are described.Type: GrantFiled: March 7, 1986Date of Patent: May 31, 1988Assignee: International Genetic Engineering, Inc.Inventors: George C. Fareed, Arup Sen
-
Patent number: 4748109Abstract: The invention provides a reagent and assay to detect, inter alia anogenital warts, cervical intraepithelial neoplasia and invasive squamous cell carcinoma of the uterine cervix using disrupted Papillomavirus virions or antigen extract thereof.Type: GrantFiled: July 2, 1984Date of Patent: May 31, 1988Inventor: Phillip J. Baird
-
Patent number: 4745053Abstract: A process for producing HuIFN using whole human blood and a method for assaying the blood interferon (HuIFN) productivity are disclosed. The whole blood is incubated in the presence of an anticoagulant (e.g. heparin, ACD, and CPD) and a viral inducer under the conditions appropriate to accumulate a substantial amount of HuIFN. The blood HuIFN productivity determined by titrating the accumulated HuIFN with a suitable procedure (bioassay, radioimmunoassay, or enzyme-linked immunosorbent assay) is useful in clinical test to detect cancer in its early stage. The HuIFN per se is recovered, and purified prior to its prophylactic and therapeutic uses.Type: GrantFiled: June 26, 1984Date of Patent: May 17, 1988Assignee: Kabushiki Kaisha Hayashibara Seibutsu Kagaku KenkyojoInventor: Masakazu Mitsuhashi
-
Patent number: 4743543Abstract: Detection of an identified human carcinoma tumor antigen in a pathological sample by means of a labelled monoclonal antibody specific to the determinant site on the antigen is enhanced and/or accelerated at an earlier development stage than heretofore achieved by removing a carbohydrate steric hindrance for monoclonal antibody availability to bind the antigen of the tumor for which it is specific. The carbohydrate steric hindrance for monoclonal binding to the antigen is identified as sialic acid. The method of the invention involves selective removal of sialic acid from the antigen's determinant site by enzymatic digestion using neuraminidase.Type: GrantFiled: September 9, 1985Date of Patent: May 10, 1988Assignee: Coulter CorporationInventor: Kenneth H. Kortright